Stockscreener 앱 받기
162.29
2.33%
-3.87
시장 영업 전:
161.79
-0.50
-0.31%
Krystal Biotech Inc 주식(KRYS)의 최신 뉴스
Krystal Biotech Presents Promising Gene Therapy at ARVO - TipRanks
Krystal Biotech Q1 2025 Earnings Preview - MSN
Krystal Biotech Inc (KRYS) Q1 2025 Earnings Report Preview: What to Look For - GuruFocus
Krystal Biotech (KRYS) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Chardan Capital Forecasts Krystal Biotech FY2025 Earnings - Defense World
Where are the Opportunities in (KRYS) - news.stocktradersdaily.com
Commit To Purchase Krystal Biotech At $150, Earn 16.3% Annualized Using Options - Nasdaq
Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Krystal Biotech shares rise as H.C. Wainwright lifts price target By Investing.com - Investing.com Canada
Krystal Biotech (NASDAQ:KRYS) Given New $240.00 Price Target at HC Wainwright - Defense World
Krystal Biotech’s VYJUVEK gets European approval for DEB treatment - Investing.com
Here's How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years - Benzinga
Demystifying Krystal Biotech: Insights From 7 Analyst Reviews - Benzinga
Krystal Biotech (KRYS) Price Target Increased to $240 by H.C. Wa - GuruFocus
Krystal Biotech's Vyjuvek gains European approval for rare skin disease treatmentPittsburgh Business Times - The Business Journals
Krystal Biotech gets EU approval for Vyjuvek (KRYS:NASDAQ) - Seeking Alpha
Krystal Biotech Gets EU Approval to Market Treatment for Dystrophic Epidermolysis Bullosa - marketscreener.com
Krystal Biotech Gains EU Approval for VYJUVEK® - TipRanks
Krystal Biotech’s VYJUVEK gets European approval for DEB treatment By Investing.com - Investing.com Canada
Krystal Biotech (KRYS) Gains EC Approval for VYJUVEK in DEB Trea - GuruFocus
Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa - The Manila Times
Krystal Biotech Receives European Approval for VYJUVEK® to Treat Dystrophic Epidermolysis Bullosa from Birth - Nasdaq
Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa - GlobeNewswire Inc.
Envestnet Asset Management Inc. Has $1.82 Million Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Acquired by LPL Financial LLC - Defense World
Wells Fargo & Company MN Boosts Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Pittsburgh biotech firms benefit in potential pharma tariffs and domestic manufacturing shift - The Business Journals
Krystal Biotech, Inc. to Present Innovative Genetic Medicine Programs at Upcoming Scientific Conferences - Nasdaq
Krystal Biotech to Present at Upcoming Scientific Conferences - The Manila Times
IBD Rating Upgrades: Krystal Biotech Flashes Improved Relative Price Strength - MSN
Bank of Montreal Can Has $521,000 Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Top Growth Companies With High Insider Ownership In April 2025 - simplywall.st
Krystal Biotech to Report First Quarter 2025 Financial Results on May 6, 2025 - The Manila Times
Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Bought by Alliancebernstein L.P. - Defense World
Wellington Management Group LLP Sells 976 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Average Recommendation of “Buy” from Analysts - Defense World
Gene Therapy Market Top Players-Krystal Biotech, Inc., - openPR.com
JPMorgan Chase & Co. Buys 23,934 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Krystal Biotech Becomes Oversold (KRYS) - Nasdaq
Krystal Biotech subsidiary Jeune Aesthetics taps Botox veteran as new CEO - The Business Journals
Is Kiniksa Pharmaceuticals (KNSA) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Krystal gets positive EU regulatory opinion for Vyjuvek - MSN
Jeune Aesthetics names Marc Forth as new CEO By Investing.com - Investing.com South Africa
Jeune Aesthetics names Marc Forth as new CEO - Investing.com Australia
Jeune Aesthetics Appoints Marc Forth As Chief Executive Officer - MarketScreener
Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer - GlobeNewswire
Aesthetic Medicine Powerhouse: BOTOX Veteran Takes Helm at Jeune Aesthetics - Stock Titan
5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025 - Zacks Investment Research
Krystal Biotech Q1 EPS Forecast Reduced by William Blair - Defense World
Krystal Biotech: Some Uncertainty, Some Value (NASDAQ:KRYS) - Seeking Alpha
Norges Bank Purchases New Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
William Blair Raises Earnings Estimates for Krystal Biotech - Defense World
Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by Sei Investments Co. - Defense World
Commonwealth Equity Services LLC Boosts Stake in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
0.39%
3.66%
자본화:
|
볼륨(24시간):